

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO   |   |    |   | <b>Complete if Known</b> |                        |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: October 21, 2008<br><br><i>(use as many sheets as necessary)</i> |   |    |   | Application Number       | 10/014,887             |
|  |   |    |   | Filing Date              | 6/14/2000              |
|  |   |    |   | First Named Inventor     | Geoffrey W. Krissansen |
|  |   |    |   | Art Unit                 | 1642                   |
|  |   |    |   | Examiner Name            | Lei Yao                |
| Sheet  | 1 | of | 6 | Attorney Docket Number   | 093397-0401            |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |  |
|-----------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |  |
|                       | P1                    | 3,678,077                                | 07-18-1972                     | Nakanishi, et al.                                  |  |
|                       | P2                    | 4,602,034                                | 07-22-1986                     | Briet, et al.                                      |  |
|                       | P3                    | 4,704,355                                | 11-03-1987                     | Bernstein, et al.                                  |  |
|                       | P4                    | 5,126,129                                | 06-30-1992                     | Wilttrout, et al.                                  |  |
|                       | P5                    | 5,464,826                                | 11-07-1995                     | Grindey, et al.                                    |  |
|                       | P6                    | 6,174,873                                | 01-16-2001                     | Wrenn, S. M.                                       |  |
|                       | P7                    | 6,194,454                                | 02-27-2001                     | Dow, R. L.   |  |
|                       | P8                    | 6,806,257                                | 10-19-2004                     | Lee, et al.  |  |
|                       | P9                    | 2001-0041713                             | 11-15-2001                     | Waldstreicher, et al.                              |  |
|                       | P10                   | 2004-0087611                             | 05-06-2004                     | Baguley, et al.                                    |  |
|                       | P11                   | 2004-0204480                             | 10-14-2004                     | Wilson, et al.                                     |  |
|                       | P12                   | 2005-0131059                             | 06-16-2005                     | Wang, et al.                                       |  |
|                       | P13                   | 2006-0009505                             | 01-12-2006                     | Baguley, et al.                                    |  |
|                       | P14                   | 2007-0060637                             | 03-15-2007                     | Wilson, et al.                                     |  |
|                       | P15                   | 2007-0082937                             | 04-12-2007                     | Baguley, et al.                                    |  |
|                       | P16                   | 2008-0070847                             | 03-20-2008                     | Wilson, et al.                                     |  |
|                       | P17                   | 2008-0070848                             | 03-20-2008                     | Wilson, et al.                                     |  |
|                       | P18                   | 2008-0070849                             | 03-20-2008                     | Wilson, et al.                                     |  |
|                       | P19                   | 2008-0070886                             | 03-20-2008                     | Wilson, et al.                                     |  |

| UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS |                       |   |  |  |  |
|---|-----------------------|---|--|--|--|
| Examiner Initials*                            | Cite No. <sup>1</sup> | U.S. Patent Application Document                | Filing Date of<br>Cited Document<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|   |                       | Serial Number-Kind Code <sup>2</sup> (if known) |  |  |  |
|   | U1                    | 12/064,632                                      | 08-28-2006                                     | Green, et al.                                      |  |
|   | U2                    | 12/064,633                                      | 08-25-2006                                     | Green, et al.                                      |  |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |   |  |                |
|--------------------------|-----------------------|---|--------------------------------|---|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Documents | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |                                |   |  |                |
|                          | F1                    | DE 2015265 A1   | 10-08-1970                     | Yoshitomi Pharmaceutical Industries, Ltd.           |  | No             |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO<br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>Date Submitted: October 21, 2008<br><i>(use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 10/014,887             |
|  |   |    |   | Filing Date              | 6/14/2000              |
|  |   |    |   | First Named Inventor     | Geoffrey W. Krissansen |
|  |   |    |   | Art Unit                 | 1642                   |
|  |   |    |   | Examiner Name            | Lei Yao                |
| Sheet  | 2 | of | 6 | Attorney Docket Number   | 093397-0401            |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |   |  |                |
|--------------------------|-----------------------|---|--------------------------------|---|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>2</sup> Number <sup>4</sup> Kind<br>Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Documents | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|                          | F2                    | EP 0551200 A1   | 07-14-1993                     | National University of Singapore                    |  |                |
|                          | F3                    | GB 0121285.1  | 09-03-2001                     | Cancer Research Ventures, Ltd.                      |  |                |
|                          | F4                    | GB 0206839.3  | 05-01-2002                     | Cancer Research Ventures, Ltd.                      |  |                |
|                          | F5                    | GB 0225508.1  | 11-01-2002                     | Cancer Research Technology Ltd.                     |  |                |
|                          | F6                    | GB 0157387.7  | 08-25-2006                     | Antisoma Research Ltd.                              |  |                |
|                          | F7                    | GB 0157386.9  | 08-25-2006                     | Antisoma Research Ltd.                              |  |                |
|                          | F8                    | GB 0604114.9  | 03-02-2006                     | Antisoma Research Ltd.                              |  |                |
|                          | F9                    | NZ 506060   | 07-28-2000                     | Auckland Uniservices, Ltd.                          |  |                |
|                          | F10                   | WO 03/020259 A2   | 03-13-2003                     | Cancer Research Technology Ltd.                     |  |                |
|                          | F11                   | WO 03/080044  | 10-02-2003                     | Cancer Research Technology Ltd.                     |  |                |
|                          | F12                   | WO 04/039363  | 05-13-2004                     | Cancer Research Technology Ltd.                     |  |                |
|                          | F13                   | WO 05/027974 A1   | 03-31-2005                     | Cancer Research Technology Ltd.                     |  |                |
|                          | F14                   | WO 07/023302  | 03-01-2007                     | Antisoma PLC  |  |                |
|                          | F15                   | WO 07/023307  | 03-01-2007                     | Antisoma PLC  |  |                |
|                          | F16                   | WO 91/04014   | 04-04-1991                     | Synergen, Inc.                                      |  |                |
|                          | F17                   | WO 96/32418 A1  | 10-17-1996                     | Laboratoires OM S.A.                                |  |                |
|                          | F18                   | WO 96/36347A1   | 11-21-1996                     | Eli Lilly and Co.                                   |  |                |
|                          | F19                   | WO 97/04761 A1  | 02-13-1997                     | Trustees of Boston University                       |  |                |
|                          | F20                   | WO 98/25615 A1  | 06-18-1998                     | Eli Lilly and Co.                                   |  |                |
|                          | F21                   | WO 98/25616 A1  | 06-18-1998                     | Eli Lilly and Co.                                   |  |                |
|                          | F22                   | WO 98/42334 A1  | 10-01-1998                     | Eli Lilly and Co.                                   |  |                |
|                          | F23                   | WO 98/42345 A1  | 10-01-1998                     | Eli Lilly and Co.                                   |  |                |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO   |   |    |   | <b>Complete if Known</b> |                        |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: October 21, 2008<br><br><i>(use as many sheets as necessary)</i> |   |    |   | Application Number       | 10/014,887             |
|  |   |    |   | Filing Date              | 6/14/2000              |
|  |   |    |   | First Named Inventor     | Geoffrey W. Krissansen |
|  |   |    |   | Art Unit                 | 1642                   |
|  |   |    |   | Examiner Name            | Lei Yao                |
| Sheet  | 3 | of | 6 | Attorney Docket Number   | 093397-0401            |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.              | T <sup>6</sup> |
|                                 | D1                    | ARBUCK, et al.; "An Overview of Topoisomerase I-Targeting Agents"; Semin. Hematol. 1998, 35(3 supp. 4):3-12.  |                |
|                                 | D2                    | ATWELL, et al.; "Potential Antitumor Agents. 60. Relationships between Structure and in Vivo Colon 38 Activity for 5-Substituted 9-Oxoxanthene-4-acetic Acids"; J. Med. Chem. (1990), 33:1375-1379.   |                |
|                                 | D3                    | AVASTIN. <a href="http://www.centerwatch.com/patient/drugs/dru851.html">http://www.centerwatch.com/patient/drugs/dru851.html</a> , June 29, 2006.   |                |
|                                 | D4                    | BAGULEY, et al.; Poster Abstract 138, of abstracts book for the 16th EORTC-NCI-AACR 2004 meeting on "Molecular Targets and Cancer Therapeutics"; Geneva, Switzerland (28 September to 1 October, 2004).   |                |
|                                 | D5                    | BAGULEY, et al.; "Potential of DMXAA combination therapy for solid tumors"; Expert Rev. Anticancer Ther. (2002), 2(5):593-603.  |                |
|                                 | D6                    | BAREFOOT, R.; "Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs"; Journal of Chromatography B (2001), 751:205-211.   |                |
|                                 | D7                    | BEGLEY, et al.; "The Blood-Brain-Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System"; J. Pharm. Pharmacol. (1996), 48:136-146.  |                |
|                                 | D8                    | BIBBY, et al.; "Flavone acetic acid - from laboratory to clinic and back"; Anti-Cancer Drugs (1993), 4:3-17.  |                |
|                                 | D9                    | BIBBY, et al.; "Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy"; J. Natl. Cancer Inst. (1989), 81:216-220.   |                |
|                                 | D10                   | BREM, et al.; "Interstitial chemotherapy with drug polymer implants for the treatment of recurring gliomas"; J. Neurosurg. (1991), 74:441-446.  |                |
|                                 | D11                   | CALABRESI, et al.; "The Pharmacological Basis of Therapeutics, Ninth Edition," (1996), Goodman & Gilman's The Pharmacological Basis of Therapeutics. Section X, Chemotherapy of Neoplastic Diseases, pages 1225-1229.   |                |
|                                 | D12                   | CHING, et al.; "The Anti-Tumour and Immune-Modulatory Activities of Flavone Acetic and Xanthone Acetic Acids"; 1990; N.P. Das (ed.), flavonoids in Biology and Medicine III. Proceedings of the 3rd International Symposium on Flavonoids in Biology and Medicine; 381-391. |                |
|                                 | D13                   | COLOMA, et al.; "Transport across the primate Blood-Brain-Barrier of a genetically engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor"; Pharmaceutical Research (2000), 17(3):266-274.   |                |
|                                 | D14                   | CORBETT, et al.; "Activity of flavone acetic acid (NSC-347512) against solid tumors of mice"; Investigational New Drugs (1986), 4:207-220.  |                |
|                                 | D15                   | DJEHA, et al.; "Synergistic in vivo antitumor activity in lung and colon cancer xenografts with the vascular disrupting agent DMXAA combined with bevacizumab"; Proc. Am. Assoc. Cancer. Res. Annual Meeting, (2006), 47:55.  |                |
|                                 | D16                   | ECONOMOU, et al.; "Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo"; Immunology (1989), 67:514-519.  |                |
|                                 | D17                   | GALBRAITH, et al.; "Effects of 5,6-Dimethylxanthone-4-acetic acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-enhanced Magnetic Resonance Imaging"; J. Clinical Oncology (2002), 20(18):3826-3840.   |                |
|                                 | D18                   | GRAHAM, et al.; Fresh from the Pipeline: Cetuximab"; Nature Reviews Drug Discovery (2004), 3:549-550.   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |                               |                        |
|--|---|-------------------------------|------------------------|
| Substitute for form 1449/PTO   |   | <b>Complete if Known</b>      |                        |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: October 21, 2008<br><br><i>(use as many sheets as necessary)</i> |   | <b>Application Number</b>     | 10/014,887             |
|  |   | <b>Filing Date</b>            | 6/14/2000              |
|  |   | <b>First Named Inventor</b>   | Geoffrey W. Krissansen |
|  |   | <b>Art Unit</b>               | 1642                   |
|  |   | <b>Examiner Name</b>          | Lei Yao                |
| <b>Sheet</b>   | 4 | of                            | 6                      |
|  |   | <b>Attorney Docket Number</b> | 093397-0401            |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|                                 | D19                   | GRIFFIOEN, et al.; "Angiogenesis Inhibitors Overcome Tumor Induced Endothelial Cell Anergy"; Int. J. Cancer (1999), 80:315-319.  |                |
|                                 | D20                   | JAMESON, et al.; "Clinical aspects of a phase I trial of 5,6-dimethylxanthene-4-acetic acid (DMXAA), a novel antivasular agent"; British Journal of Cancer (2003), 88:1844-1850.   |                |
|                                 | D21                   | JAMESON, et al.; "Phase I Pharmacokinetic and Pharmacodynamic Study of 5,6-Dimethylxanthene-4-Acetic Acid (DMXAA), A Novel Antivasular Agent"; Proc. Am. Soc. Clin Oncol. (2000), 19: 182a.  |                |
|                                 | D22                   | JOHNSON, et al.; "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials"; British J. of Cancer (2001), 84(10):1424-1431.  |                |
|                                 | D23                   | KELLAND, L.; "Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment"; Curr.Cancer. Ther. Rev. (2005), 1(1):1-9.  |                |
|                                 | D24                   | KROLL, et al.; "Improving Drug Delivery to Intracerebral Tumor and Surrounding Brain in a Rodent Model: A Comparison of Osmotic versus Bradykinin Modification of the Blood-Brain and/or Blood-Tumor Barriers"; Neurosurgery (1998), 43(4):879-886.            |                |
|                                 | D25                   | LANGER, R.; "New Methods of Drug Delivery"; Science (1990), 249:1527-1533.   |                |
|                                 | D26                   | MAIER, et al.; "In-Vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11"; Anti-Cancer Drugs (1997), 8:238-244.  |                |
|                                 | D27                   | MARNETT, L.J.; "Aspirin and Related Nonsteroidal Anti-inflammatory Drugs as Chemopreventive Agents against Colon Cancer"; Preventive Medicine 24,103-106 (1995)  |                |
|                                 | D28                   | MARONA, H.; "Synthesis and Properties of Some Xanthone-2-Alkylcarboxylic acids and Xanthone-2-Glyoxal"; Polish Journal of Chemistry, 54:2059 (1980).   |                |
|                                 | D29                   | McKEAGE, et al.; "5,6-Dimethylxanthene-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent"; Clin. Cancer Res. (2006), 12(6):1776-1784.   |                |
|                                 | D30                   | NAKAMURA, et al.; "Antitumor Effect of Recombinant Human Interleukin 1 Alpha against Murine Syngeneic Tumors"; Jpn. J. Cancer Research (Gann) (1986), 77:767-773.  |                |
|                                 | D31                   | NAKANISHI, et al.; "Carboxylic Acids"; Chem. Abstr. 76:126784w (1972), (Abstract of Japan A-7,200,425)   |                |
|                                 | D32                   | NAKANISHI, et al.; "Studies of Anti-Inflammatory Agents XXXI; Studies on the Synthesis and Anti-Inflammatory Activity of Xanthenyl- and Benzo-pyranopyridinylacetic acid Derivatives"; Yakugaku Zasshi (1976), 96:99-109.                                      | Yes            |
|                                 | D33                   | NEUWELT, et al.; "Increased Delivery of Tumor-specific Monoclonal Antibodies to Brain after Osmotic Blood-Brain-Barrier modification in Patients with Melanoma Metastatic to the Central Nervous System"; Neurosurgery (1987), 20(6):885-895.                  |                |
|                                 | D34                   | NISHINO, et al.; "Oxidation of 9-Xanthenones with Lead (IV) Acetate. Formation of Di-gamma-lactones"; Bull. Chem Soc. Jpn. (1983), 56:2847-48.   |                |
|                                 | D35                   | NISHINO, et al.; "Regioselective Carboxylation of 9-Xanthenones with Manganese (III) Acetate." Bull. Chem Soc. Jpn. (1983), 56:474-480.  |                |
|                                 | D36                   | O'REILLY, et al.; "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth"; Cell (1997), 88:277-285.   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO   |   |    |   | <b>Complete if Known</b> |                        |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: October 21, 2008<br><br><i>(use as many sheets as necessary)</i> |   |    |   | Application Number       | 10/014,887             |
|  |   |    |   | Filing Date              | 6/14/2000              |
|  |   |    |   | First Named Inventor     | Geoffrey W. Krissansen |
|  |   |    |   | Art Unit                 | 1642                   |
|  |   |    |   | Examiner Name            | Lei Yao                |
| Sheet  | 5 | of | 6 | Attorney Docket Number   | 093397-0401            |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.                 | T <sup>6</sup> |
|                                 | D37                   | PECKHAM, et al.; "Oxford Textbook of Oncology". Oxford University Press, Vol 1. p.451, 1995.   |                |
|                                 | D38                   | PLOWMAN, et al.; "Flavone Acetic Acid: A Novel Agent with Preclinical Antitumor Activity Against Colon Adenocarcinoma 38 in Mice"; Cancer Treatment Reports (1986), 70(5):631-635.   |                |
|                                 | D39                   | PTCL. Chemical and Other Safety Information. "ptcl.chem.ox.ac.uk/MSDS"   |                |
|                                 | D40                   | REWCASTLE, et al.; "Potential Antitumor Agents. 62. Structure-Activity Relationships for Tricyclic Compounds Related to the Colon Tumor Active Drug 9-Oxo-9H-xanthene-4-acetic Acid"; J. Med. Chem. (1991), 34:491-496.  |                |
|                                 | D41                   | RIECKMANN, et al.; "Okadaic Acid is a potent inducer of AP-1, NF-kappa-B, and Tumor-Necrosis Factor-alpha in Human B Lymphocytes"; Biochem. Biophys. Res. Commun. (1992), 187(1):51-57.  |                |
|                                 | D42                   | RUSTIN et al.; "5,6-Dimethylxanthene-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study"; British Journal of Cancer (2003), 88:1160-1167.   |                |
|                                 | D43                   | RUSTIN et al.; "Impact on Tumour Perfusion Measured by Dynamic Magnetic Resonance Imaging (MRI), in the Phase 1 Trial of 5,6-dimethylxanthene-4-acetic Acid (DMXAA)"; Proc. 10th NCI-EORTC Symp. New Drugs (1998), 10:126.   |                |
|                                 | D44                   | SALTIEL, E.; "Erlotinib". <a href="http://www.medicinenet.com/erlotinib/article.htm">http://www.medicinenet.com/erlotinib/article.htm</a> . Nov 28, 2004.  |                |
|                                 | D45                   | SALTIEL, E.; "Gefitinib". <a href="http://www.medicinenet.com/gefitinib/article.htm">http://www.medicinenet.com/gefitinib/article.htm</a> . June 22, 2005.   |                |
|                                 | D46                   | SAUSVILLE, et al.; "Contributions of human tumor xenografts to anticancer drug development"; Cancer Research (2006), 66(7):3351-3354.  |                |
|                                 | D47                   | SHOEMAKER, et al.; "Pleiotropic Resistance and Drug Development"; Cancer Drug Resistance (1986), 143-149.  |                |
|                                 | D48                   | SHOWALTER, H.; "Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids"; Chemtracts: Org. Chem. (1991), 4(2): 168-171. Commentary of REWCASTLE: J. Med. Chem. (1991), 34:217-222. |                |
|                                 | D49                   | SIEMANN, et al.; "Enhanced Antitumor Efficacy through the combination of Vascular Targeting Agents and Conventional Anticancer Drugs"; Proceedings of the American Association for Cancer Research (2000), 41:525.   |                |
|                                 | D50                   | SIEMANN, et al.; "Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumor Therapy"; Int. J. Cancer (2002), 99:1-6.  |                |
|                                 | D51                   | SIIM, et al.; "Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthene-4-acetic acid (DMXAA)"; Cancer Chemother Pharmacol (2003), 51:43-52.  |                |
|                                 | D52                   | SIMONE, et al.; "Oncology". Cecil Text Book of Medicine. 20th Edition Vol 1, W. B. Saunders Company. 1997, p1004-1010.   |                |
|                                 | D53                   | TEMSAMANI, et al.; "Brain drug delivery technologies: novel approaches for transporting therapeutics"; Pharm. Sci. Technology Today (2000), 3(5):155-162.  |                |
|                                 | D54                   | TYLE, P.; "Ionophoretic Devices for Drug Delivery"; Pharmaceutical Research (1986), 3(6):318-326.  |                |
|                                 | D55                   | VAN MOORSEL, et al.; "Combination Chemotherapy Studies with Gemcitabine and Etoposide in Non-Small Cell Lung and Ovarian Cancer Cell Lines"; Biochemical Pharmacology (1999), 57:407-415.  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO   |   |    |   | <b>Complete if Known</b> |                        |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: October 21, 2008<br><br><i>(use as many sheets as necessary)</i> |   |    |   | Application Number       | 10/014,887             |
|  |   |    |   | Filing Date              | 6/14/2000              |
|  |   |    |   | First Named Inventor     | Geoffrey W. Krissansen |
|  |   |    |   | Art Unit                 | 1642                   |
|  |   |    |   | Examiner Name            | Lei Yao                |
| Sheet  | 6 | of | 6 | Attorney Docket Number   | 093397-0401            |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.       | T <sup>6</sup> |
|                                 | D56                   | WESTLAND, et al.; "Activated non-neural specific T cells open the blood-brain-barrier to circulating antibodies"; Brain (1999), 122:1283-1291.   |                |
|                                 | D57                   | WIESENTHAL. "Is one 'sensitive' drug better than another? Can you detect drug synergy? What are the best drug combinations?" <a href="http://weisenthal.org/feedback.html">http://weisenthal.org/feedback.html</a> , 2/04/2002.                                      |                |
|                                 | D58                   | WILKINSON, et al.; "Tamoxifen (Noivadex*) Therapy - Rationale for Loading Dose Followed by Maintenance Dose for Patients with Metastatic Breast Cancer"; Cancer Chemotherapy Pharmacol. (1982), 10:33-35.  |                |
|                                 | D59                   | WOUTERS, et al.; "Hypoxia as a target for combined modality treatments"; European J. Cancer (2002), 38:240-257.  |                |
|                                 | D60                   | ZAHARKO, et al.; "Therapeutic and Pharmacokinetic Relationships of Flavone Acetic Acid: An Agent with Activity Against Solid Tumors"; Cancer Treatment Reports (2002), 70(12):1415-1421.   |                |
|                                 | D61                   | ZHANG, et al.; "Conjugation of brain-derived neurotrophic factor to a blood-brain-barrier resistant drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin"; Brain Research (2001), 889:49-56. |                |
|                                 | D62                   | ZHAO, et al.; "Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthene-4-acetic acid by optimal scheduling"; Clinical Cancer Research (2003), 9:6545-6550.   |                |
|                                 | D63                   | ZHAO, et al.; "Oral activity and pharmacokinetics of 5,6-dimethylxanthene acetic acid (DMXAA) in mice"; Cancer Chemother. Pharmacol. (2002), 49:20-26.   |                |
|                                 | D64                   | ZHOU, et al.; "Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthene-4-acetic (DMXAA) by human liver microsomes"; J. Clin. Pharmacol. (2001), 52:129-136.  |                |
|                                 | D65                   | ZWI, et al.; "Blood Flow Failure as a Major Determinant in the Antitumor Action of Flavone Acetic Acid"; J. Natl. Cancer Inst. (1989), 81:1005-1013.   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.